The oncobiome; what, so what, now what?

Abstract

Microbial communities inhabiting various body sites play critical roles in the initiation, progression, and treatment of cancer. The gut microbiota, a highly diverse microbial ecosystem, interacts with immune cells to modulate inflammation and immune surveillance, influencing cancer risk and therapeutic outcomes. Local tissue microbiota may impact the transition from premalignant states to malignancy. Characterization of the intratumoral microbiota increasingly reveals distinct microbiomes that may influence tumor growth, immune responses, and treatment efficacy. Various bacteria species have been reported to modulate cancer therapies through mechanisms such as altering drug metabolism and shaping the tumor microenvironment (TME). For instance, gut or intratumoral bacterial enzymatic activity can convert prodrugs into active forms, enhancing therapeutic effects or, conversely, inactivating small-molecule chemotherapeutics. Specific bacterial species have also been linked to improved responses to immunotherapy, underscoring the microbiome’s role in treatment outcomes. Furthermore, unique microbial signatures in cancer patients, compared with healthy individuals, demonstrate the diagnostic potential of microbiota. Beyond the gut, tumor-associated and local microbiomes also affect therapy by influencing inflammation, tumor progression, and drug resistance. This review explores the multifaceted relationships between microbiomes and cancer, focusing on their roles in modulating the TME, immune activation, and treatment efficacy. The diagnostic and therapeutic potential of bacterial members of microbiota represents a promising avenue for advancing precision oncology and improving patient outcomes. By leveraging microbial biomarkers and interventions, new strategies can be developed to optimize cancer diagnosis and treatment.

Keywords

Microbiome / cancer / tumor microenvironment / cancer therapy / DNA

References

[1] Bray F,Sung H.Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2024;74:229-63

[2] Soerjomataram I.Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070.Nat Rev Clin Oncol2021;18:663-72

[3] Berg G,Fischer D.Microbiome definition re-visited: old concepts and new challenges.Microbiome2020;8:103 PMCID:PMC7329523

[4] Doré J.Human-microbes symbiosis in health and disease, on earth and beyond planetary boundaries.Front Astron Space Sci2023;10:1180522

[5] Sepich-Poore GD,Straussman R,Wargo JA.The microbiome and human cancer.Science2021;371:eabc4552 PMCID:PMC8767999

[6] Sadrekarimi H,Bakhshesh M.Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora.J Transl Med2022;20:301 PMCID:PMC9258144

[7] Thomas RM.The microbiome and cancer: is the ‘oncobiome’ mirage real?.Trends Cancer2015;1:24-35 PMCID:PMC4642279

[8] Sipos A,Mikó E.The role of the microbiome in ovarian cancer: mechanistic insights into oncobiosis and to bacterial metabolite signaling.Mol Med2021;27:33 PMCID:PMC8017782

[9] Li R,Xu Y.Fusobacterium nucleatum and colorectal cancer.Infect Drug Resist2022;15:1115-20 PMCID:PMC8937307

[10] Joo JE,Georgeson P.Intratumoral presence of the genotoxic gut bacteria pks⁺ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.Br J Cancer2024;130:728-40 PMCID:PMC10912205

[11] Chakaroun RM,Kovacs P.Gut microbiome, intestinal permeability, and tissue bacteria in metabolic disease: perpetrators or bystanders?.Nutrients2020;12:1082 PMCID:PMC7230435

[12] Kennedy MS.The microbiome: composition and locations.Prog Mol Biol Transl Sci2020;176:1-42 PMCID:PMC8025711

[13] Wilde J,Foster KR.Host control of the microbiome: mechanisms, evolution, and disease.Science2024;385:eadi3338

[14] Donaldson GP,Yu KB.Gut microbiota utilize immunoglobulin A for mucosal colonization.Science2018;360:795-800 PMCID:PMC5973787

[15] Lenoir M,Torres-Maravilla E.Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3.Gut Microbes2020;12:1-16 PMCID:PMC7567499

[16] Aindelis G.Modulation of anti-tumour immune responses by probiotic bacteria.Vaccines2020;8:329 PMCID:PMC7350223

[17] de Martel C, Georges D, Bray F, Ferlay J, Clifford GM. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis.Lancet Glob Health2020;8:e180-90

[18] Shanahan F,O’Toole PW.The healthy microbiome-what is the definition of a healthy gut microbiome?.Gastroenterology2021;160:483-94

[19] Gupta VK,Bakshi U.A predictive index for health status using species-level gut microbiome profiling.Nat Commun2020;11:4635 PMCID:PMC7492273

[20] Ward DV,Rojas-Correa M.The intestinal and oral microbiomes are robust predictors of COVID-19 severity the main predictor of COVID-19-related fatality. medRxiv 2021.

[21] Gumenyuk LN,Silaeva NV.Gut microbiota alterations and their relationship to the disease severity and some cytokine profile indicators in patients with COVID-19.Bull Russ State Med Univ2022;22-9Available from: https://cyberleninka.ru/article/n/gut-microbiota-alterations-and-their-relationship-to-the-disease-severity-and-some-cytokine-profile-indicators-in-patients-with. [Last accessed 25 Feb 2025]

[22] Kumavath R,Paul S,Busi S.Effects of gut microbiome and obesity on the development, progression and prevention of cancer (Review).Int J Oncol2024;64:4

[23] Qiu Q,Ma Y.Exploring the emerging role of the gut microbiota and tumor microenvironment in cancer immunotherapy.Front Immunol2020;11:612202 PMCID:PMC7817884

[24] Liou JM, Malfertheiner P, Lee YC, et al; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020;69:2093-112. PMCID:PMC11321410

[25] Ekström AM,Hansson LE,Nyrén O.Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection.Gastroenterology2001;121:784-91

[26] Uemura N,Yamamoto S.Helicobacter pylori infection and the development of gastric cancer.N Engl J Med2001;345:784-9

[27] Matsuda H,Takeoka T.Helicobacter pylori infection affects the tumor immune microenvironment of esophageal cancer patients.Anticancer Res2024;44:3799-805

[28] Wang C,Shao L.Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases.Eur J Med Res2023;28:484 PMCID:PMC10626716

[29] Manos J.The human microbiome in disease and pathology.APMIS2022;130:690-705 PMCID:PMC9790345

[30] Radocchia G,Marazzato M. Chronic Intestinal Pseudo-Obstruction (CIPO): interplay between enteric nervous system, serotonin and mucosa-associated microbiota. 2023. Available from: https://iris.uniroma1.it/handle/11573/1700117. [Last accessed on 25 Feb 2025]

[31] Song M,Sun J.Influence of the gut microbiome, diet, and environment on risk of colorectal cancer.Gastroenterology2020;158:322-40 PMCID:PMC6957737

[32] Zhao L,Zuo T.The composition of colonic commensal bacteria according to anatomical localization in colorectal cancer.Engineering2017;3:90-7

[33] Han S,Wu Y,Yang X.Progress in research on colorectal cancer-related microorganisms and metabolites.Cancer Manag Res2020;12:8703-20 PMCID:PMC7518784

[34] Wu X,He L,Wang X.Effects of the intestinal microbial metabolite butyrate on the development of colorectal cancer.J Cancer2018;9:2510-7 PMCID:PMC6036887

[35] Liu B,Sartor RB.Antigen-presenting cell production of IL-10 inhibits T-helper 1 and 17 cell responses and suppresses colitis in mice.Gastroenterology2011;141:653-62.e4 PMCID:PMC4651012

[36] Park I,Won S.Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease.Sci Rep2024;14:16122 PMCID:PMC11245548

[37] Yang Y,Su Q.The mediation/moderation effects of gut microbiota on sleep quality and primary liver cancer: a mendelian randomization and case-control study.Nat Sci Sleep2024;16:663-74 PMCID:PMC11152056

[38] Wen Y,Qiu H.Gut microbiota affects obesity susceptibility in mice through gut metabolites.Front Microbiol2024;15:1343511 PMCID:PMC10916699

[39] Méndez-Sánchez N,Vera-Barajas A.The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer.Hepatoma Res2020;6:5 PMCID:PMC7313221

[40] Ginès P,Abraldes JG,Fabrellas N.Liver cirrhosis.Lancet2021;398:1359-76

[41] Zheng Z.The gut-liver axis in health and disease: the role of gut microbiota-derived signals in liver injury and regeneration.Front Immunol2021;12:775526 PMCID:PMC8703161

[42] Doden H,Devendran S.Metabolism of oxo-bile acids and characterization of recombinant 12α-hydroxysteroid dehydrogenases from bile acid 7α-dehydroxylating human gut bacteria.Appl Environ Microbiol2018;84:e00235-18 PMCID:PMC5930368

[43] Liu Y,Zhou W,Xu H.Secondary bile acids and tumorigenesis in colorectal cancer.Front Oncol2022;12:813745 PMCID:PMC9097900

[44] Engelmann C,Sharma S.Toll-like receptor 4 is a therapeutic target for prevention and treatment of liver failure.J Hepatol2020;73:102-12

[45] Fan H,Han M.Multi-omics-based investigation of Bifidobacterium’s inhibitory effect on glioma: regulation of tumor and gut microbiota, and MEK/ERK cascade.Front Microbiol2024;15:1344284 PMCID:PMC11064926

[46] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[47] Nakatsu G,MacDonald MH.Interactions between diet and gut microbiota in cancer.Nat Microbiol2024;9:1644-54

[48] Wu Z,Zhang R.Sex differences in colorectal cancer: with a focus on sex hormone-gut microbiome axis.Cell Commun Signal2024;22:167 PMCID:PMC10921775

[49] Sosnowski K.Ethanol-induced changes to the gut microbiome compromise the intestinal homeostasis: a review.Gut Microbes2024;16:2393272 PMCID:PMC11376419

[50] Dono A,Rodriguez-Armendariz AG.Glioma and the gut–brain axis: opportunities and future perspectives.Neurooncol Adv2022;4:vdac054 PMCID:PMC9113089

[51] Cummins J.Bacteria and tumours: causative agents or opportunistic inhabitants?.Infect Agent Cancer2013;8:11 PMCID:PMC3668256

[52] Justiz-Vaillant A,Mohammed M.Narrative literature review on risk factors involved in breast cancer, brain cancer, colon rectal cancer, gynecological malignancy, lung cancer, and prostate cancer. 2021.

[53] Urbaniak C,Brackstone M.Microbiota of human breast tissue.Appl Environ Microbiol2014;80:3007-14 PMCID:PMC4018903

[54] Lehouritis P,Stanton M.Local bacteria affect the efficacy of chemotherapeutic drugs.Sci Rep2015;5:14554 PMCID:PMC4586607

[55] Dohlman AB,Ding S.The cancer microbiome atlas: a pan-cancer comparative analysis to distinguish tissue-resident microbiota from contaminants.Cell Host Microbe2021;29:281-98.e5 PMCID:PMC7878430

[56] Gerasimova Y,Nadeem U.Challenges for pathologists in implementing clinical microbiome diagnostic testing.J Pathol Clin Res2024;10:e70002 PMCID:PMC11407905

[57] Walker SP,Claesson MJ.Sequence-based characterization of intratumoral bacteria - a guide to best practice.Front Oncol2020;10:179 PMCID:PMC7046755

[58] Massier L,Stumvoll M,Chakaroun R.Tissue-resident bacteria in metabolic diseases: emerging evidence and challenges.Nat Metab2024;6:1209-24

[59] Davis NM,Holmes SP,Callahan BJ.Simple statistical identification and removal of contaminant sequences in marker-gene and metagenomics data.Microbiome2018;6:226 PMCID:PMC6298009

[60] Bueso Y, Walker SP, Hogan G, Claesson MJ, Tangney M. Protoblock - a biological standard for formalin fixed samples.Microbiome2020;8:122 PMCID:PMC7443293

[61] Bueso Y, Walker SP, Tangney M. Characterization of FFPE-induced bacterial DNA damage and development of a repair method.Biol Methods Protoc2020;5:bpaa015 PMCID:PMC7548031

[62] Walker SP,Hogan G,Claesson MJ.Non-specific amplification of human DNA is a major challenge for 16S rRNA gene sequence analysis. Sci Rep 2020;10:16356. PMCID:PMC7529756

[63] Hogan G,Narayanen N.Biopsy bacterial signature can predict patient tissue malignancy.Sci Rep2021;11:18535 PMCID:PMC8448740

[64] Mascitti M,Troiano G.Beyond head and neck cancer: the relationship between oral microbiota and tumour development in distant organs.Front Cell Infect Microbiol2019;9:232 PMCID:PMC6607058

[65] Xuan C,Chung A.Microbial dysbiosis is associated with human breast cancer.PLoS One2014;9:e83744 PMCID:PMC3885448

[66] Wen L,Lu H.Porphyromonas gingivalis promotes oral squamous cell carcinoma progression in an immune microenvironment.J Dent Res2020;99:666-75

[67] Chen XX,Wang Y.Acetate-producing bacterium Paenibacillus odorifer hampers lung cancer growth in lower respiratory tract: an in vitro study.Microbiol Spectr2024;12:e0071924 PMCID:PMC11537125

[68] Fang X,Wu S,Zhu J.The role of intratumoral microorganisms in the progression and immunotherapeutic efficacy of head and neck cancer.Oncologie2024;26:349-60

[69] Sanegre S,Burgos-Panadero R,Noguera R.Integrating the tumor microenvironment into cancer therapy.Cancers2020;12:1677 PMCID:PMC7352326

[70] Wu Z,Guo Y.The role of Fusobacterium nucleatum in colorectal cancer cell proliferation and migration.Cancers2022;14:5350 PMCID:PMC9656216

[71] Yang Y,Li WK.Multi-Omics analysis elucidates tumor microenvironment and intratumor microbes of angiogenesis subtypes in colon cancer.World J Gastrointest Oncol2024;16:3169-92 PMCID:PMC11271793

[72] Yang X,Chen C.Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment.Immunology2021;164:476-93 PMCID:PMC8517597

[73] Crowther M,Bishop ET.Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors.J Leukoc Biol2001;70:478-90

[74] Dora D,Soós Á.From bench to bedside: an interdisciplinary journey through the gut-lung axis with insights into lung cancer and immunotherapy.Front Immunol2024;15:1434804 PMCID:PMC11410641

[75] Wang W,Huang X.Microbiota and glioma: a new perspective from association to clinical translation.Gut Microbes2024;16:2394166 PMCID:PMC11352717

[76] Yan J,Ren Q.Gut microbiota as a biomarker and modulator of anti-tumor immunotherapy outcomes.Front Immunol2024;15:1471273 PMCID:PMC11634861

[77] Usyk M,Hayes RB.Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.Genome Med2021;13:160 PMCID:PMC8513370

[78] Alexander JL,Teare J,Nicholson JK.Gut microbiota modulation of chemotherapy efficacy and toxicity.Nat Rev Gastroenterol Hepatol2017;14:356-65

[79] Baruch EN,Ben-Betzalel G.Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science2021;371:602-9

[80] Griffin ME,Becker JL.Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy.Science2021;373:1040-6 PMCID:PMC9503018

[81] Dai Y,Liu W,Hu W.Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.J Cancer Res Clin Oncol2021;147:1379-88

[82] Voorde J, Vervaeke P, Liekens S, Balzarini J. Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs.FEBS Open Bio2015;5:634-9 PMCID:PMC4541722

[83] Souza RO,Quintanilha MF.Evaluation of the treatment with Akkermansia muciniphila BAA-835 of chemotherapy-induced mucositis in mice.Probiotics Antimicrob Proteins2024;16:275-92

[84] Mi H,Zhang B.Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats.Cell Physiol Biochem2017;42:2330-41

[85] Yin B,Yuan F,Lu P.Research progress on the effect of gut and tumor microbiota on antitumor efficacy and adverse effects of chemotherapy drugs.Front Microbiol2022;13:899111 PMCID:PMC9538901

[86] Lehouritis P,McCarthy FO,Tangney M.Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.J Control Release2016;222:9-17

[87] Dharmaraja AT.Role of reactive oxygen species (ROS) in therapeutics and drug resistance in cancer and bacteria.J Med Chem2017;60:3221-40

[88] Wei L,Xian CJ.Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating Toll-like receptor signaling pathways.Int J Mol Sci2021;22:9474 PMCID:PMC8431669

[89] Son MY.Anticancer effects of gut microbiota-derived short-chain fatty acids in cancers.J Microbiol Biotechnol2023;33:849-56 PMCID:PMC10394342

[90] Gasaly N,Gotteland M.Butyrate and the fine-tuning of colonic homeostasis: implication for inflammatory bowel diseases.Int J Mol Sci2021;22:3061 PMCID:PMC8002420

[91] Al-Qadami GH,Subramaniam CB,Bowen JM.Gut microbiota-derived short-chain fatty acids: impact on cancer treatment response and toxicities.Microorganisms2022;10:2048 PMCID:PMC9612155

[92] Gong S,Zeng Y.Gut microbiota accelerates cisplatin-induced acute liver injury associated with robust inflammation and oxidative stress in mice.J Transl Med2021;19:147 PMCID:PMC8045234

[93] Jin S,Wang S.Dioscin alleviates cisplatin-induced mucositis in rats by modulating gut microbiota, enhancing intestinal barrier function and attenuating TLR4/NF-κB signaling cascade.Int J Mol Sci2022;23:4431 PMCID:PMC9025408

[94] Wu CH,Liao JM.D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation.Ther Adv Med Oncol2019;11:1758835918821021 PMCID:PMC6376546

[95] Gui QF,Zhang CX,Yang YH.Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model.Genet Mol Res2015;14:5642-51

[96] Liu Y,Pan T,Chen W.Indole metabolites and colorectal cancer: gut microbial tryptophan metabolism, host gut microbiome biomarkers, and potential intervention mechanisms.Microbiol Res2023;272:127392

[97] Liu Y,Yu J.Microbial metabolites in colorectal tumorigenesis and cancer therapy.Gut Microbes2023;15:2203968 PMCID:PMC10132243

[98] Voelcker G.The mechanism of action of cyclophosphamide and its consequences for the development of a new generation of oxazaphosphorine cytostatics.Sci Pharm2020;88:42

[99] Mañez R,Díaz I.Removal of bowel aerobic gram-negative bacteria is more effective than immunosuppression with cyclophosphamide and steroids to decrease natural alpha-galactosyl IgG antibodies.Xenotransplantation2001;8:15-23

[100] Jung IS,Oh DS.Micronized, heat-treated Lactobacillus plantarum LM1004 alleviates cyclophosphamide-induced immune suppression.J Med Food2019;22:896-906

[101] Pereira MA,Ramos MFKP.Gastric cancer with microsatellite instability displays increased thymidylate synthase expression.J Surg Oncol2022;126:116-24

[102] Ciobanu L,Oancea DM.Effect of Lactobacillus plantarum ACTT 8014 on 5-fluorouracil induced intestinal mucositis in Wistar rats.Exp Ther Med2020;20:209 PMCID:PMC7604756

[103] Yuan L,Li H.The influence of gut microbiota dysbiosis to the efficacy of 5-fluorouracil treatment on colorectal cancer.Biomed Pharmacother2018;108:184-93

[104] Paroha S,Dubey RD.Recent advances and prospects in gemcitabine drug delivery systems.Int J Pharm2021;592:120043

[105] Geller LT,Danino T.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.Science2017;357:1156-60 PMCID:PMC5727343

[106] Gori S,Belluomini L.Gut microbiota and cancer: how gut microbiota modulates activity, efficacy and toxicity of antitumoral therapy.Crit Rev Oncol Hematol2019;143:139-47

[107] Iosifidou N,Botou M,Tatsaki E.Elucidation of the gemcitabine transporters of escherichia coli K-12 and gamma-proteobacteria linked to gemcitabine-related chemoresistance.Int J Mol Sci2024;25:7012 PMCID:PMC11241209

[108] Cruz MS,Gagliani N.Roles of microbiota in pancreatic cancer development and treatment.Gut Microbes2024;16:2320280 PMCID:PMC10900280

[109] Wang J,Yang S.SN-38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2-related factor 2 and enhances drug sensitivity of colorectal cancer cells.Mol Carcinog2024;63:742-56

[110] Mahdy MS,Dishisha T.Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity.BMC Microbiol2023;23:53 PMCID:PMC9979425

[111] Okunaka M,Matsui R,Uesawa Y.Evaluation of the expression profile of irinotecan-induced diarrhea in patients with colorectal cancer.Pharmaceuticals2021;14:377 PMCID:PMC8073045

[112] Mego M,Chovanec J.Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12® Lactobacillus rhamnosus LGG® in colorectal cancer patients.Front Oncol2023;13:1168654 PMCID:PMC10438450

[113] Liu C,Zhang D,Zhu D.Clinical cancer immunotherapy: current progress and prospects.Front Immunol2022;13:961805 PMCID:PMC9592930

[114] Miller PL.Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review.Gut Pathog2020;12:43 PMCID:PMC7488430

[115] Desilets A,Routy B.The link between the gut microbiome and response to immune checkpoint inhibitors in renal cell carcinoma.Eur Urol2021;79:1-2

[116] Shui L,Li J,Sun Q.Gut microbiome as a potential factor for modulating resistance to cancer immunotherapy.Front Immunol2019;10:2989 PMCID:PMC6978681

[117] Davar D,McCulloch JA.Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients.Science2021;371:595-602 PMCID:PMC8097968

[118] Routy B,Miller WH Jr.Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial.Nat Med2023;29:2121-32

[119] Temraz S,Nasr R,Mukherji D.Gut microbiome: a promising biomarker for immunotherapy in colorectal cancer.Int J Mol Sci2019;20:4155 PMCID:PMC6747470

[120] Frankel AE,Kim J.Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients.Neoplasia2017;19:848-55 PMCID:PMC5602478

[121] Routy B,Derosa L.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science2018;359:91-7

[122] Chaput N,Coutzac C.Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab.Ann Oncol2017;28:1368-79

[123] Matson V,Bao R.The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.Science2018;359:104-8 PMCID:PMC6707353

[124] Zhou G,Meng K.Interaction between gut microbiota and immune checkpoint inhibitor-related colitis.Front Immunol2022;13:1001623 PMCID:PMC9648670

[125] Gao Y,Sun D.Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 checkpoint blockade.Cancer Res2023;83:3710-25

[126] Zhang LL,Xing Y.Lactobacillus rhamnosus GG alleviates radiation-induced intestinal injury by modulating intestinal immunity and remodeling gut microbiota.Microbiol Res2024;286:127821

[127] Sittipo P,Park CE.Irradiation-induced intestinal damage is recovered by the indigenous gut bacteria Lactobacillus acidophilus.Front Cell Infect Microbiol2020;10:415 PMCID:PMC7461978

[128] Nada HG,Darwish NH.Lactobacillus acidophilus and Bifidobacterium longum exhibit antiproliferation, anti-angiogenesis of gastric and bladder cancer: Impact of COX2 inhibition.PharmaNutrition2020;14:100219

[129] Segers C,Claesen J.Intestinal mucositis precedes dysbiosis in a mouse model for pelvic irradiation.ISME Commun2021;1:24 PMCID:PMC9723693

[130] Armstrong JA.The effects of mucositis on quality of life in patients with head and neck cancer.Clin J Oncol Nurs2006;10:53-6

[131] Wang L,Shu Z.Quality of life and its association with radiation-induced oral mucositis in patients with nasopharyngeal carcinoma during radiotherapy: a prospective study. 2023.

[132] Wang Y,Zhang H.Probiotic Streptococcus salivarius K12 alleviates radiation-induced oral mucositis in mice.Front Immunol2021;12:684824 PMCID:PMC8213397

[133] Minervini G,Marrapodi MM.Probiotics in the treatment of radiotherapy-induced oral mucositis: systematic review with meta-analysis.Pharmaceuticals2023;16:654 PMCID:PMC10224002

[134] Ferrari V.The intratumoral microbiota: friend or foe?.Trends Cancer2023;9:472-9

[135] Zhang H,Leiliang X.Beyond the gut: the intratumoral microbiome’s influence on tumorigenesis and treatment response.Cancer Commun2024;44:1130-67 PMCID:PMC11483591

[136] Bi X,Liu C.Intratumoral microbiota: metabolic influences and biomarker potential in gastrointestinal cancer.Biomolecules2024;14:917 PMCID:PMC11353126

[137] Gao Y,Li W.Antibiotics for cancer treatment: a double-edged sword.J Cancer2020;11:5135-49 PMCID:PMC7378927

[138] Canale FP,Antonini G.Metabolic modulation of tumours with engineered bacteria for immunotherapy.Nature2021;598:662-6

[139] Zhang H,Leiliang X.Beyond the gut: the intratumoral microbiome’s influence on tumorigenesis and treatment response.Cancer Commun2024;44:1130-67 PMCID:PMC11483591

[140] Sankarapandian V,Rajendran RL.An update on the effectiveness of probiotics in the prevention and treatment of cancer.Life2022;12:59 PMCID:PMC8779143

[141] Morze J,Przybyłowicz K,Hoffmann G.An updated systematic review and meta-analysis on adherence to mediterranean diet and risk of cancer.Eur J Nutr2021;60:1561-86 PMCID:PMC7987633

[142] Sinicrope FA.Increasing incidence of early-onset colorectal cancer.N Engl J Med2022;386:1547-58

[143] Tan JK,Mackay CR.Dietary fiber and SCFAs in the regulation of mucosal immunity.J Allergy Clin Immunol2023;151:361-70

[144] Xu S,Huang C,Zhu J.Mechanisms and emerging strategies for irinotecan-induced diarrhea.Eur J Pharmacol2024;974:176614

[145] Wu M,Zou Z,Liu H.Gastrointestinal microbiota in gastric cancer: potential mechanisms and clinical applications-a literature review.Cancers2024;16:3547 PMCID:PMC11506470

[146] Lin XB,Valcheva R.The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats.PLoS One2014;9:e83644 PMCID:PMC3891650

[147] Blaževitš O,Longo VD.Fasting and fasting mimicking diets in cancer prevention and therapy.Trends Cancer2023;9:212-22

[148] Vernieri C,Ligorio F.Fasting-mimicking diet is safe and reshapes metabolism and antitumor immunity in patients with cancer.Cancer Discov2022;12:90-107 PMCID:PMC9762338

[149] Yassin MA,Aldapt MB.Effects of intermittent fasting on response to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia: an outcome of European LeukemiaNet Project.Cancer Control2021;28:10732748211009256 PMCID:PMC8204644

[150] Ogino S.The global epidemic of early-onset cancer: nature, nurture, or both?.Ann Oncol2024;35:1071-3

[151] Zhou Z,Depetris-Chauvin A.Beneficial microbiome and diet interplay in early-onset colorectal cancer.EMBO Mol Med2025;17:9-30 PMCID:PMC11730345

[152] Zhuang H,Wang L,Liu Z.Jujube powder enhances cyclophosphamide efficiency against murine colon cancer by enriching CD8⁺ T cells while inhibiting eosinophilia.Nutrients2021;13:2700 PMCID:PMC8401958

[153] Zhang M,Mao B.Ellagic acid and intestinal microflora metabolite urolithin A: a review on its sources, metabolic distribution, health benefits, and biotransformation.Crit Rev Food Sci Nutr2023;63:6900-22

[154] Reid G.Probiotics: definition, scope and mechanisms of action.Best Pract Res Clin Gastroenterol2016;30:17-25

[155] Kennedy JM,Walton GE.A review on the use of prebiotics in ulcerative colitis.Trends Microbiol2024;32:507-15

[156] Agah S,Mosavi M.More protection of Lactobacillus acidophilus than Bifidobacterium bifidum probiotics on azoxymethane-induced mouse colon cancer.Probiotics Antimicrob Proteins2019;11:857-64

[157] Heydari Z,Alizadeh AM,Khalighfard S.Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and their involving genes in mice colon cancer.Probiotics Antimicrob Proteins2019;11:1155-62

[158] Ding M,Liu F.Lactation time influences the composition of Bifidobacterium and Lactobacillus at species level in human breast milk.Benef Microbes2022;13:319-30

[159] Lee JS,Kwon OS.Anti-inflammatory actions of probiotics through activating suppressor of cytokine signaling (SOCS) expression and signaling in Helicobacter pylori infection: a novel mechanism.J Gastroenterol Hepatol2010;25:194-202

[160] Liu L.The potential of the gut microbiome to reshape the cancer therapy paradigm: a review.JAMA Oncol2022;8:1059-67

[161] Sampsell K,Ohland C.Exercise and prebiotic fiber provide gut microbiota-driven benefit in a survivor to germ-free mouse translational model of breast cancer.Cancers2022;14:2722 PMCID:PMC9179252

[162] Dahl SM,Walton GE.Gut microbial modulation by culinary herbs and spices.Food Chem2023;409:135286

[163] Mehta JP,Singhal RS.The potential of paraprobiotics and postbiotics to modulate the immune system: a review.Microbiol Res2023;275:127449

[164] Tkach S,Kuzenko I,Falalyeyeva T.Fecal microbiota transplantation in diseases not associated with Clostridium difficile: current status and future therapeutic option. In: Microbiome in 3P Medicine Strategies. Springer; 2023. pp. 275-308.

[165] Benech N,Radoszycki L,Sokol H.Patient knowledge of gut microbiota and acceptability of fecal microbiota transplantation in various diseases.Neurogastroenterol Motil2022;34:e14320

[166] Papastergiou V,Karatapanis S.Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.World J Gastroenterol2014;20:9898-911 PMCID:PMC4123371

[167] Tshibangu-Kabamba E.Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.Nat Rev Gastroenterol Hepatol2021;18:613-29

[168] Dincă AL,Mărginean CO.Old and new aspects of H. pylori-associated inflammation and gastric cancer.Children2022;9:1083 PMCID:PMC9322908

[169] Oster P,Riva E. Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies.Gut2022;71:457-66 PMCID:PMC8862014

[170] Pagani IS,Wardill HR.A gut instinct on leukaemia: a new mechanistic hypothesis for microbiota-immune crosstalk in disease progression and relapse.Microorganisms2022;10:713 PMCID:PMC9029211

[171] Varga MG,Cai H.Helicobacter pylori blood biomarkers and gastric cancer survival in China.Cancer Epidemiol Biomarkers Prev2018;27:342-4 PMCID:PMC5835187

[172] Boubrik F,El Kadmiri N.Potential non-invasive biomarkers of Helicobacter pylori-associated gastric cancer.J Gastrointest Cancer2022;53:1113-20

[173] Zhao H,Liu J.Bifidobacterium breve predicts the efficacy of anti-PD-1 immunotherapy combined with chemotherapy in Chinese NSCLC patients.Cancer Med2023;12:6325-36 PMCID:PMC10028067

[174] Liu W,Sun B.Intestinal microbiome associated with immune-related adverse events for patients treated with anti-PD-1 inhibitors, a real-world study.Front Immunol2021;12:756872 PMCID:PMC8716485

[175] Chronopoulos A.Emerging role of bacterial extracellular vesicles in cancer.Oncogene2020;39:6951-60 PMCID:PMC7557313

[176] Park JY,Seo HC.Bacteria-derived extracellular vesicles in urine as a novel biomarker for gastric cancer: integration of liquid biopsy and metagenome analysis.Cancers2021;13:4687 PMCID:PMC8468964

[177] Bryzgunova OE,Skvortsova TE.Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients.PLoS One2016;11:e0157566 PMCID:PMC4909321

[178] Cooper RM,Ng JQ.Engineered bacteria detect tumor DNA.Science2023;381:682-6 PMCID:PMC10852993

[179] Luo F,Ye C.Microbial biomarkers in liquid biopsy for cancer: an overview and future directions.Cancer Control2024;31:10732748241292019 PMCID:PMC11500238

[180] Morrissey D,Tangney M.Tumour targeting with systemically administered bacteria.Curr Gene Ther2010;10:3-14

[181] Saini G.Microbial mavericks: unleashing bacteria’s tumor-seeking superpowers in the fight against cancer.Appl Biol Chem J2023;4:113-7

[182] Lehouritis P,Tangney M.Designer bacteria as intratumoural enzyme biofactories.Adv Drug Deliv Rev2017;118:8-23

[183] Murphy C,Lehouritis P,Tangney M.Intratumoural production of TNFα by bacteria mediates cancer therapy.PLoS One2017;12:e0180034 PMCID:PMC5491124

[184] Byrne WL. Bacteria as gene therapy vectors for cancer. In: Gene and cell therapy: therapeutic mechanisms and strategies. CRC Press; 2015. Available from: https://www.routledge.com/Gene-and-Cell-Therapy-Therapeutic-Mechanisms-and-Strategies-Fourth-Edition/SmythTempleton/p/book/9781466571990?srsltid=AfmBOorPTytVFRrTCxxv9gJArg_2-LWOw78Q61XmP1zNlMWb57lUieod. [Last accessed on 25 Feb 2025]

[185] Gao P,Xu G.Harnessing and mimicking bacterial features to combat cancer: from living entities to artificial mimicking systems.Adv Mater2024;36:e2405075

[186] Allemailem KS.Innovative approaches of engineering tumor-targeting bacteria with different therapeutic payloads to fight cancer: a smart strategy of disease management.Int J Nanomedicine2021;16:8159-84 PMCID:PMC8687692

[187] Bueso Y, Lehouritis P, Tangney M. In situ biomolecule production by bacteria; a synthetic biology approach to medicine.J Control Release2018;275:217-28

[188] Byrne WL,Cronin M,Tangney M.Bacterial-mediated DNA delivery to tumour associated phagocytic cells.J Control Release2014;196:384-93

[189] Janku F,Pezeshki A.Intratumoral injection of Clostridium novyi-NT spores in patients with treatment-refractory advanced solid tumors.Clin Cancer Res2021;27:96-106

[190] Chowdhury S,Coker C,Arpaia N.Programmable bacteria induce durable tumor regression and systemic antitumor immunity.Nat Med2019;25:1057-63 PMCID:PMC6688650

[191] Wu L,Li S.Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma.Acta Pharm Sin B2022;12:3952-71 PMCID:PMC9532557

[192] Cronin M,Murphy C.Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.Mol Ther2014;22:1188-97 PMCID:PMC4048890

[193] Li Z,Liu J.Chemically and biologically engineered bacteria-based delivery systems for emerging diagnosis and advanced therapy.Adv Mater2021;33:e2102580

[194] Tahmasebi H,Monemi M.From cure to crisis: understanding the evolution of antibiotic-resistant bacteria in human microbiota.Biomolecules2025;15:93 PMCID:PMC11764262